OSE Immunotherapeutics Past Earnings Performance
Past criteria checks 0/6
OSE Immunotherapeutics's earnings have been declining at an average annual rate of -35.7%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 13.7% per year.
Key information
-35.7%
Earnings growth rate
-31.8%
EPS growth rate
Biotechs Industry Growth | 30.8% |
Revenue growth rate | -13.7% |
Return on equity | -100.1% |
Net Margin | -1,032.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Oct 02We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Apr 30OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be
May 11Is OSE Immunotherapeutics (EPA:OSE) A Risky Investment?
May 08Imagine Holding OSE Immunotherapeutics (EPA:OSE) Shares While The Price Zoomed 322% Higher
Mar 16How Is OSE Immunotherapeutics' (EPA:OSE) CEO Paid Relative To Peers?
Dec 01Revenue & Expenses BreakdownBeta
How OSE Immunotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 2 | -23 | 8 | 17 |
30 Sep 23 | 3 | -25 | 9 | 20 |
30 Jun 23 | 4 | -28 | 10 | 22 |
31 Mar 23 | 11 | -23 | 10 | 24 |
31 Dec 22 | 18 | -18 | 10 | 27 |
30 Sep 22 | 26 | -13 | 10 | 29 |
30 Jun 22 | 33 | -7 | 11 | 30 |
31 Mar 22 | 30 | -12 | 12 | 30 |
31 Dec 21 | 26 | -17 | 12 | 30 |
30 Sep 21 | 20 | -21 | 11 | 29 |
30 Jun 21 | 14 | -25 | 9 | 28 |
31 Mar 21 | 12 | -21 | 8 | 25 |
31 Dec 20 | 10 | -17 | 7 | 22 |
30 Sep 20 | 13 | -12 | 7 | 22 |
30 Jun 20 | 16 | -8 | 7 | 22 |
31 Mar 20 | 21 | -6 | 6 | 22 |
31 Dec 19 | 26 | -5 | 6 | 22 |
30 Sep 19 | 23 | -4 | 5 | 19 |
30 Jun 19 | 20 | -3 | 5 | 16 |
31 Mar 19 | 22 | 1 | 5 | 16 |
31 Dec 18 | 24 | 5 | 4 | 15 |
30 Sep 18 | 24 | 5 | 4 | 15 |
30 Jun 18 | 24 | 5 | 5 | 15 |
31 Mar 18 | 16 | -3 | 5 | 15 |
31 Dec 17 | 7 | -11 | 5 | 15 |
30 Sep 17 | 5 | -10 | 5 | 13 |
30 Jun 17 | 3 | -10 | 4 | 11 |
31 Mar 17 | 2 | 5 | 4 | 8 |
31 Dec 16 | 0 | 21 | 3 | 5 |
30 Sep 16 | 0 | 21 | 3 | 4 |
30 Jun 16 | 0 | 22 | 3 | 3 |
31 Mar 16 | 0 | 8 | 3 | 3 |
31 Dec 15 | 0 | -6 | 3 | 2 |
30 Sep 15 | 0 | -5 | 3 | 2 |
30 Jun 15 | 0 | -5 | 2 | 2 |
31 Mar 15 | 0 | -4 | 2 | 2 |
31 Dec 14 | 0 | -3 | 1 | 2 |
30 Sep 14 | 0 | -2 | 1 | 1 |
30 Jun 14 | 0 | -1 | 0 | 0 |
31 Mar 14 | 0 | -1 | 0 | 0 |
Quality Earnings: OSE is currently unprofitable.
Growing Profit Margin: OSE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OSE is unprofitable, and losses have increased over the past 5 years at a rate of 35.7% per year.
Accelerating Growth: Unable to compare OSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OSE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: OSE has a negative Return on Equity (-100.12%), as it is currently unprofitable.